Nipah virus (NiV) is a zoonotic henipavirus associated with sporadic outbreaks and high casefatality. In clinical practice, the main threat is not only individual severity—often characterized byencephalitis and/or severe respiratory failure—but also the potential for healthcare-associatedtransmission when early suspicion and infection prevention and control (IPC) measures aredelayed. This narrative review connects key aspects of NiV biology with bedside decision-makingin emergency and critical care settings. We emphasize the mechanistic entry axis (G glycoproteinbinding to ephrin-B2/B3 receptors followed by F-mediated membrane fusion) as a unifyingframework that explains tissue tropism for endothelium and the central nervous system, and thatalso informs investigational countermeasures (neutralizing antibodies and vaccines targetingentry). We summarize transmission pathways (bat-to-human, animal-to-human, and person-toperson), typical incubation and symptom patterns, diagnostic approaches (RT-PCR and serology)and biosafety considerations, and practical management centered on high-quality supportivecritical care and strict IPC. Finally, we briefly review the current landscape of therapeutic andvaccine research, highlighting that no licensed specific treatment or vaccine exists to date.